Table 3.
Comparison of prevalence of high risk factors for CVD in HIV subjects
| Modifiable ASCVD risk factor | Parameter | Cutoff level for CVD risk | HIV naïve (n = 100) Prevalence% (95% CI) |
HIV treated (n = 100) Prevalence% (95% CI) |
z-test p-value |
|---|---|---|---|---|---|
| Obesity | Body Mass Index | ≥ 30kg/m2 | 13% (7 – 19%) | 17% (10 – 25%) | 0.43 |
| Waist Circumference | |||||
| Women | > 88cm | 18% (11 – 25%) | 27% (19 – 34%) | 0.13 | |
| Men | > 102cm | 6% (2 – 11%) | 9% (4 – 15%) | 0.42 | |
| Waist-to-Hip Ratio | |||||
| Women | > 0.85 | 26% (18 – 34%) | 28% (20 – 35%) | 0.75 | |
| Men | > 0.9 | 13% (7 – 19%) | 15% (9 – 20%) | 0.68 | |
| Hypertension | Systolic BP | > 140 mmHg | 12% (6 – 19%) | 23% (15 – 31%) | 0.04+ |
| Diastolic BP | > 90 mmHg | 11% (6 – 19%) | 20% (11 – 28%) | 0.08 | |
| Diabetes mellitus | Glucose | > 7.0mmol/L | 2% (1 – 4%) | 9% (4 – 16%) | 0.03+ |
| Dyslipidaemia | Total Cholesterol | ≥ 5.2mmol/L | 34% (26 – 43%) | 47% (38 – 55%) | 0.06 |
| Triglyceride | ≥ 1.7mmol/L | 21% (14 – 29%) | 24% (15 – 32%) | 0.61 | |
| LDL-C | ≥ 3.3mmol/L | 30% (22 – 39%) | 37% (28 – 46%) | 0.29 | |
| HDL-C | < 1.0 mmol/L | 42% (33 – 50%) | 11% (5 – 17%) | <0.001+ | |
| Inflammation | hsCRP | ≥ 2 mg/L | 51% (42 – 59%) | 36% (27 – 46%) | 0.03+ |
| Atherothrombosis | Homocysteine | > 12 umol/L | 35% (26 – 44%) | 39% (29 – 49%) | 0.56 |
+
statistically significant at <0.05